RNA, U4atac small nuclear 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4ATAC2P profile across patient tissues and cancer cell-line models. RNU4ATAC2P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, RNU4ATAC2P is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, RNU4ATAC2P RNA expression shows 10,968 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight TGCT, and KICH as cancer lineages where RNU4ATAC2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4ATAC2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4ATAC2P survival associations across molecular data types. RNU4ATAC2P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4ATAC2P RNA expression–survival associations across cancer types. High RNU4ATAC2P expression shows unfavorable associations in TGCT, OV, THCA, READ and BLCA, but favorable associations in ESCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for RNU4ATAC2P RNA expression.
This table summarizes RNU4ATAC2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4ATAC2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4ATAC2P shows lower tumor expression in LUAD and higher tumor expression in KICH. The KICH box plot shows higher RNU4ATAC2P RNA expression in tumor versus normal tissue (log2 FC = +0.360, t-test p = .002).
This table shows molecular features associated with RNU4ATAC2P in patient tissues and cancer cell lines. In patient samples, RNU4ATAC2P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
